The White House threw its weight behind efforts to help US biotech compete with China, using the administration’s budget proposal to outline FDA policy changes

Amgen said that an injectable version of its eye drug Tepezza succeeded in a Phase 3 study for thyroid eye disease, setting up a showdown

Plus: Debt financing deals for Apnimed and Opus Genetics Anthropic buys a stealth biotech: The San Francisco artificial intelligence giant is buying Coefficient Bio, building

Takeda’s ongoing restructuring has hit another Denali program as an eight-year-old partnership comes to an end between the two companies. Takeda returned the full rights

In response to a warning letter from the FDA that accused the company of making “false or misleading” claims about its bladder cancer drug Anktiva,